Vol. 142 No. 2526 (2012)
Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years?
- Christine Jacobsen
- Philipp Metzler
- Joachim Anton Obwegeser
- Wolfgang Zemann
- Klaus Wilhelm Grätz
QUESTIONS UNDER STUDY: 8 years after discovery of osteonecrosis of the jaw associated with bisphosphonate therapy a lot of experience has been garnered in treating 112 patients with this disease. This disease, although uncommon, is still a burden for the patient as well as the treating specialists and an adequate standardised classification as well as therapy does not exist. This article presents a summary of collected patient data, garnered experience and consequential changes in knowledge, in diagnostic measures and therapy.
METHODS: The data of in total 112 patients referred to the Special Clinics for patients with bisphosphonate-associated lesions of the jaw was retrospectively analysed and compared with data from the literature.
RESULTS: In total, 110 patients, 70% women, were included in the data analysis. A quarter of those patients had osteoporosis as the underlying disease, more than half of all patients had extractions as the local influencing factor. The lesion was localised in the mandible in three quarters of all patients and almost all patients showed clinical signs of infection. In total, 58% of all patients were treated surgically with a complete remission rate of 78% over 7 years.
CONCLUSIONS: This summary of patient data and literature shows that knowledge about bisphosphonate-associated osteopathology of the jaw becomes more and more specific. The range of drugs associated with this disease has increased, but also therapeutic options show more and more success. Classifications, published shortly after the discovery of BRONJ need to be revised and new knowledge included.
- Dannemann C, Zwahlen R, Grätz KW. Clinical experiences with bisphopsphonate induced osteochemonecrosis of the jaws. Swiss Med Wkly. 2006;136(31–32):504–9.
- Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009;44(1):4–10.
- Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41(3):318–20.
- Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoOaMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–76.
- Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg. 2009;67(12):2698–9.
- Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, et al. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol. 2011;29(17):e521–2; author reply e23–4.
- Yarom N, Elad S, Madrid C, Migliorati CA. Osteonecrosis of the jaws induced by drugs other than bisphosphonates – a call to update terminology in light of new data. Oral Oncol. 2010;46(1):e1.
- Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.
- Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218(1):47–54.
- Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23(6):826–36.
- Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head & face medicine. 2010;6(1):11.
- Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011;40(3):277–84.
- Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243–53.
- Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42(5):841–7.
- Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136(8):1117–24.
- Thumbigere-Math V, Sabino MaC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009;67(9):1904–13.
- Abu-Id MH, Açil Y, Gottschalk J, Kreusch T. Bisphosphonate-associated osteonecrosis of the jaw. Mund-, Kiefer- und Gesichtschirurgie: MKG 2006;10(2):73–81.
- Katz J, Gong Y, Salmasinia D, Hou W, Burkley B, Ferreira P, et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2011;40(6):605–11.
- Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356–62.
- Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011;1218(1):38–46.
- Reddy GK, Mughal TI, Roodman GD. Novel approaches in the management of myeloma-related skeletal complications. Support Cancer Ther. 2006;4(1):15–8.
- Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2011.
- Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg. 2010.
- Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2009:1–3.
- Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99–102; discussion 99–02.
- Subramanian G, Cohen HV, Quek SYP. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide’s potential role in its resolution. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2011.
- Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg. 2010;68(4):790–6.
- Goss A, Bartold M, Sambrook P, Hawker P. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg. 2010;68(2):337–43.
- Jacobsen C, Metzler P, Rossle M, Obwegeser J, Zemann W, Gratz KW. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig. 2012.
- Martin DC, O'Ryan FS, Indresano AT, Bogdanos P, Wang B, Hui RL, et al. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg. 2010;68(3):508–14.
- Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaws – characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40(4):303–9. Epub 2011 Jun 14.
- Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010;68(4):797–804.
- Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, et al. Actinomycosis of the jaws – histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 2007;451(6):1009–17.
- Kaplan I, Anavi K, Anavi Y, Calderon S, Schwartz-Arad D, Teicher S, et al. The clinical spectrum of Actinomyces-associated lesions of the oral mucosa and jawbones: correlations with histomorphometric analysis. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2009;108(5):738–46.
- Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009;45(5):843–52.
- Kassolis JD, Scheper M, Jham B, Reynolds MA. Histopathologic findings in bone from edentulous alveolar ridges: a role in osteonecrosis of the jaws? Bone. 2010;47(1):127–30.
- Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide oftype I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(12):2644–8.
- Lee CYS, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature. Implant dentistry. 2009;18(6):492–500.
- Dodson TB. CTX and its role in managing patients exposed to oral bisphosphonates. J Oral Maxillofac Surg. 2010;68(2):487–8; author reply 88–9.
- Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis. 2009;15(8):527–37.
- Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg. 2008;66(7):1516–7.
- Morag Y, Morag-Hezroni M, Jamadar DA, Ward BB, Jacobson JA, Zwetchkenbaum SR, et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics: a review publication of the Radiological Society of North America, Inc 2009;29(7):1971–84.
- Gill SB, Valencia MP, Sabino MLC, Heideman GM, Michel MA. Bisphosphonate-related osteonecrosis of the mandible and maxilla: clinical and imaging features. J Comput Assist Tomogr. 2009;33(3):449–54.
- Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):75–84.
- Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(3):358–64.
- O’Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67(7):1363–72.
- Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, et al. Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009;50(8):1385; author reply 85.
- Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009;50(1):30–5.
- Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20(2):331–6.
- Gevorgyan A, Enepekides DJ. Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare. Curr Opin Otolaryngol Head Neck Surg. 2008;16(4):325–30.
- Adamo V, Caristi N, Saccà MM, Ferraro G, Arcanà C, Maisano R, et al. Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Expert Opin Pharmacother. 2008;9(8):1351–61.
- Engroff SL, Kim DD. Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg. 2007;65(11):2374–85.
- Erkan M, Bilgi O, Mutluoğlu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP. 2009;10(5):579–80; author reply 81–2.
- Scoletta M, Arduino PG, Reggio L, Dalmasso P, Mozzati M. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed Laser Surg. 2010;28(2):179–84.
- Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(2):153–63.
- Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg. 2010;39(3):251–5.
- Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):85–95.
- Marx RE. Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):107–19.
- Brock G, Barker K, Butterworth CJ, Rogers S. Practical considerations for treatment of patients taking bisphosphonate medications: an update. Dent Update 2011;38(5):313–4, 17–8, 21–4 passim.
- Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg. 2010;68(1):107–10.